WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Fluence Bioengineering
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
MEDICAL
Felix Biotechnology | January 08, 2021
Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and...
US Drug Test | July 21, 2020
US Drug Test Centers, one of the largest testing companies in the United States, announced they are now offering COVID-19 Antibody Testing with FDA Emergency Use Authorization at 1,800+ locations nationwide. No prescription is necessary. To book an appointment, visit www.usdrugtestcenters.com, select a location, order a test and an order from a local doctor will be sent to you in 6-12 hours. The test includes a simple blood draw, and results are received usually within 24-48 hours.Antibody...
FierceBiotech | February 10, 2020
Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....
PR Newswire | August 26, 2020
Bolder BioTechnology, Inc. announced today that preclinical studies have shown that its proprietary long-acting interferon beta analog, BBT-032, strongly inhibits growth of the SARS-CoV-2 virus in culture at concentrations expected to be readily achievable in patients. SARS-CoV-2 is the coronavirus responsible for the Covid-19 pandemic.Based upon these promising results, Bolder BioTechnology intends to file an Investigational New Drug Application with the U.S. Food and Drug Administration ...
INDUSTRIAL IMPACT
Whitepaper
CELL AND GENE THERAPY
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE